Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Relmada Therapeutics reported its Q3 2024 financial results, highlighting a cash position of $54.1 million, which supports operations into 2025. Key developments include a Phase 3 interim analysis for REL-1017 and a Phase 1 study for REL-P11, both expected by the end of 2024.
November 07, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Relmada Therapeutics reported a cash position of $54.1 million, supporting operations into 2025. The upcoming Phase 3 interim analysis for REL-1017 and Phase 1 study for REL-P11 are key milestones.
The financial results show a strong cash position, which is crucial for funding upcoming clinical trials. The anticipated Phase 3 interim analysis for REL-1017 and the start of the Phase 1 study for REL-P11 are significant events that could positively impact the stock if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100